Table 4 Results of model analysis (deterministic and probabilistic sensitivity analysis)
LY (95% CI) | QALY (95% CI) | Cost, € (95% CI) | |
|---|---|---|---|
Deterministic analysis (undiscounted) | |||
Cetuximab + BSC | 0.61 | 0.48 | 37,146 |
BSC | 0.32 | 0.24 | 3678 |
Incremental | 0.29 | 0.25 | 33,468 |
ICER | 115,690 | 134,495 | |
Deterministic analysis (discounted) | |||
Cetuximab + BSC | 0.61 | 0.48 | 36,637 |
BSC | 0.32 | 0.23 | 3648 |
Incremental | 0.29 | 0.25 | 32,989 |
ICER | 114,907 | 133,527 | |
PSA (undiscounted) | |||
Cetuximab + BSC | 0.61 (0.57–0.64) | 0.48 (0.45–0.51) | 36,915 (26,773–48,716) |
BSC | 0.32 (0.30–0.34) | 0.24 (0.22–0.25) | 3639 (2520–4982) |
Incremental | 0.29 (0.25–0.33) | 0.25 (0.21–0.28) | 33,276 (22,720–45,027) |
ICER | 116,030 (80,417–158,009) | 134,777 (92,521–184,072) | |
PSA (discounted) | |||
Cetuximab + BSC | 0.61 (057–0.64) | 0.48 (0.45–0.51) | 36,410 (26,407–48,053) |
BSC | 0.32 (0.30–0.34) | 0.24 (0.22–0.25) | 3609 (2498–4942) |
Incremental | 0.29 (0.24–0.33) | 0.25 (0.21–0.28) | 32,801 (22,394–44,397) |
ICER | 115,248 (79,861–156,946) | 133,812 (92,521–184,072) | |